Tao Chen is part of a new generation of pharmaceutical analytical scientists helping to reshape how drugs are developed and understood. At Genentech, her work sits at the intersection of analytical chemistry and emerging therapeutic modalities, where robust characterization and high-quality data are becoming ever more central to innovation.
Featured in The Analytical Scientist’s 2022 Top 40 Under 40 Power List, Chen also authored one of the winning essays in our 2025 Power List – Leading Voices Edition. Alongside her work at Genentech, she serves on the Executive Committee of the Chinese American Chromatography Association and has been recognized with awards including the 2024 Enabling Technologies Consortium Recognition Award.
In this first installment of our new Frontline Pharma series, we spoke with Chen about her path into industry and the analytical advances shaping the future of biopharmaceutical development.
What led you to pursue a career in industry over academia?
I was drawn to industry because of the opportunity to translate science into tangible impact. In pharma, analytical work directly informs decisions that shape real medicines – therapies that ultimately reach patients. There is a strong sense of urgency and responsibility that comes with this work, and that deeply resonates with me.
Industrial research is inherently mission-driven and anchored in a strong sense of purpose: projects are centered on unmet medical needs, guided by well-defined development goals, timelines, and milestones. You can see how your work is positively impacting someone else’s life, and sometimes, that impact is a matter of life or death, which is tremendously powerful, humbling, and inspiring.
What advice would you give to early-career scientists weighing a future in academia versus industry?
For early-career analytical scientists, my first piece of advice is to think beyond technical excellence and reflect on what genuinely motivates you and fulfills you. What kind of problems energize you: open-ended, curiosity-driven questions, or goal-oriented challenges with defined deliverables? How do you want to spend your day-to-day time? Writing grants and mentoring students or participating in cross-functional discussions and driving projects forward as part of a broader team? There is no right or wrong answer, only the career path that fits you best.
If those reflections point toward an industry career, here are a few additional pieces of advice you might find helpful. I strongly encourage young scientists to develop both technical depth and breadth. Establish yourself as an expert in a specific area, whether that’s chromatography, mass spectrometry, or new modality characterization, while maintaining a working understanding of adjacent disciplines – such as process chemistry, formulation science, and regulatory strategy. At the same time, technical proficiency alone is not enough. How you communicate, collaborate, and prioritize can be just as important as what you know. Soft skills truly matter.
Find your community and learn from others, especially those more senior than you. Build connections. These often become your professional tribe and extended scientific family. And remember to give back whenever you can; mentoring and supporting others is often just as fulfilling as being mentored yourself. Finally, think deliberately about your long-term career development. And perhaps most importantly, do work that truly interests you. If a path no longer fits, it’s okay to let go and pivot. Scientific careers are marathons, not straight lines.
How is analytical science perceived across the biopharmaceutical industry, and how do you respond to that perception?
While analytical science is still sometimes framed as a support function, particularly by those outside of the analytical chemistry field, its true role is far more central and essential. In practice, it is the backbone of biopharmaceutical innovation. Across the industry, there is growing recognition, particularly with the rise of complex new modalities, that robust analytical characterization is indispensable to successful drug development.
Analytical science underpins nearly every aspect of the drug development lifecycle. During API development, it enables reaction understanding, impurity profiling, and route optimization. In drug product development, it guides excipient selection, formulation design, and stability assessment. It ensures manufacturing robustness, supports regulatory filings, and most critically, protects patient safety by defining and monitoring critical quality attributes. Looking forward, the integration of automation and ML/AI into drug development is an inevitable trend, and analytical science is central to this transformation through the efficient generation of high-quality data to power these advanced workflows.
That said, perceptions still vary depending on organizational maturity and modality focus. Teams working on biologics, nucleic acids, or cell and gene therapies tend to appreciate analytical science as a strategic partner rather than a downstream service provider. As molecules become more complex and development becomes increasingly data driven, I believe this integrative view will only continue to strengthen.
What do you see as the biggest unmet analytical needs or bottlenecks across the drug development pipeline today?
One of the most significant challenges is the development of robust, fit-for-purpose analytical methods and strategies for increasingly complex therapeutic modalities. These methods are often difficult and time-consuming to develop and establish, particularly when structural complexity, product heterogeneity and instability are intrinsic to the modality.
Another major bottleneck lies in the practical integration of automation, high-throughput analytics, and AI/ML into routine analytical workflows. While these concepts are widely discussed, implementation remains uneven. What the industry needs are not buzzwords, but systems that are reliable, scalable, and clearly add value, tools that accelerate decision-making rather than introduce additional layers of complexity.
As therapeutic modalities become more complex, how is analytical science adapting?
Analytical science is evolving rapidly to meet these challenges through advances in instrumentation, automation, and data analysis approaches. High-resolution separations, multi-attribute methods, and increasingly sophisticated automation workflows are becoming essential. At the same time, improved data processing tools and the seamless integration of AI/ML are enabling true lab-in-the-loop.
Despite this progress, important gaps remain. One persistent challenge is the characterization of highly complex and heterogeneous products, such as ADCs, cell-based therapies, complex drug delivery systems, like lipid nanoparticles, where population-averaged measurements can obscure functionally relevant subpopulations. Another limitation is analytical resolution and efficiency for very large molecules, particularly megadalton-scale new modalities, such as mRNA and plasmid DNA. Achieving intact-level characterization with sufficient sensitivity, throughput, and robustness remains a critical challenge for critical quality attribute understanding and effective control strategy design.
Where do you see the most exciting opportunities – and biggest challenges – in applying AI and ML to analytical workflows?
The most exciting opportunities lie in automating method development, data processing and interpretation, as well as uncovering non-obvious insights within complex, multidimensional datasets. When paired with high-quality analytical data, AI/ML models can enable predictive insights that significantly accelerate development timelines and improve decision quality.
The challenges, however, are substantial. Data quality and curation remain foundational, but consistently achieving both is both difficult and time-consuming. AI/ML cannot compensate for poorly designed experiments or low-quality data. Regulatory acceptance and compliance considerations must also be addressed thoughtfully, particularly with respect to model transparency and lifecycle management. Finally, integrating AI/ML tools into legacy lab and IT systems is often non-trivial and requires sustained investment, cultural change, and cross-functional alignment.
What does successful cross-functional collaboration look like in practice?
Successful collaboration begins with early and sustained analytical involvement, ideally from end to end across the product lifecycle. Analytical scientists should be engaged from the earliest stages of development, not just when data are needed, and continue through late-stage development and life-cycle management. This enables process and formulation strategies to be shaped with an analytical mindset from the outset.
Equally important is mutual education and respect. Analytical scientists must understand process and formulation constraints, while partner teams need to appreciate analytical method limitations and uncertainties. When expectations are aligned and scientific trade-offs are openly discussed, collaboration becomes not only more efficient, but also more impactful.
Looking ahead, what does the next 5–10 years of biopharmaceutical development look like – and how critical will analytical advances be?
The next decade will be defined by increasingly complex and diverse therapeutic modalities, higher degree of personalization, broader automation implementation, and deeper integration of AI/ML across research, development, and manufacturing. Analytical science will not simply support this transformation; it will enable it.
Advanced analytical technologies will be essential for comprehensive characterization of new modalities, for real-time process monitoring in increasingly decentralized and personalized manufacturing models, and for generating the high-integrity, multidimensional datasets required to train predictive AI/ML models. In this future, analytical science is not simply a supporting function; it is a strategic driver of innovation, speed, and confidence in drug development.
Newsletters
Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.
